Bismuth subnitrate


Generic Medicine Info
Indications and Dosage
Oral
H. pylori infection
Adult: 300 mg once daily or 75 mg 4 times daily. Usually used in combination with other drugs as part of the triple therapy.
Renal Impairment
Moderate-severe impairment: Avoid use.
Contraindications
Impaired renal function; pregnancy (3rd trimester).
Special Precautions
Monitor renal function regularly.
Adverse Reactions
Nausea, vomiting, methemoglobinaemia, encephalopathy, bone and joint toxicity, darkening or blackening of faeces.
Overdosage
Overdosage may lead to serious adverse effects such as renal failure, encephalopathy and neurotoxicity. May consider gastric lavage, purgation and hydration. Chelating agents may be useful.
Drug Interactions
Increased absorption with antisecretory drugs. Reduces absorption of tetracyclines.
Action
Description:
Mechanism of Action: Bismuth subnitrate has been used for its supposed antacid and mildly astringent action in various GI disorders. It has also been used topically in the treatment of skin disorders, wounds, burns, haemorrhoids and other anorectal disorders.
Pharmacokinetics:
Absorption: Poor absorption in the GI tract. Increased gastric pH may increase bismuth absorption.
Distribution: Distributed throughout the body tissues, including bone.
Excretion: Unabsorbed bismuth is excreted in the faeces. Plasma half-life: about 5 days.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
Disclaimer: This information is independently developed by MIMS based on Bismuth subnitrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in